Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Striverdi Respimat (olodaterol) is indicated for the long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
• This summary is based on the review of seven systematic review(s)/meta-analysis(es). ^[1-7]
• Comparative Efficacy in Trough FEV1: Vilanterol/Umeclidinium demonstrated the highest efficacy with an E_max of 0.185 L, while Formoterol/Aclidinium had the lowest efficacy with an E_max of 0.119 L. Olodaterol/Tiotropium, Formoterol/Glycopyrronium, and Indacaterol/Glycopyrronium had comparable E_max values ranging from 0.150 to 0.177 L.
• COPD Exacerbation Rates at 52 Weeks: Olodaterol/Tiotropium showed a moderate or severe exacerbation rate of 38.3%, which was lower compared to other combinations such as Formoterol/Budesonide (41.0%) and Vilanterol/Umeclidinium (53.0%).
• Effectiveness in Maintenance-Naïve Patients: Tiotropium/Olodaterol significantly improved trough FEV1, SGRQ score, and TDI score at 12 weeks, with higher odds of achieving a minimal clinically important difference in these outcomes compared to Tiotropium alone.
• Tiotropium/Olodaterol 5/5 µg FDC did not significantly increase the risk of arrhythmia, heart failure, myocardial infarction, and stroke compared to monocomponents, and Olodaterol might reduce the risk of overall cardiovascular adverse events (RR 0.65).
• The use of inhaled LABAs might increase the risk of heart failure (RR 1.71), and specific caution is advised for COPD patients with a history of heart failure when using LABAs.
• Additionally, COPD patients with a history of heart failure should use LABAs cautiously due to an increased risk of heart failure.